Summary of responses
| Response category . | PTCL (n = 16) . | CTCL (n = 19) . |
|---|---|---|
| ORR (CR + PR) | ||
| ORR, n (%) | 8 (50.0) | 6 (31.6) |
| 95% Confidence interval (CI) | (24.7, 75.3) | (12.6, 56.6) |
| Best overall response, n (%) | ||
| CR | 3 (18.8) | 0 |
| PR | 5 (31.3) | 6 (31.6) |
| Stable disease | 1 (6.3) | 6 (31.6) |
| Progressive disease | 6 (37.5) | 6 (31.6) |
| Unknown | 1 (6.3) | 1 (5.3) |
| Time to response, median months (range) | 1.9 (1.6-3.5) | 2.4 (1.6-3.8) |
| PFS, median months (95% CI) | 8.3 (1.4, NR) | 4.5 (1.0-13.8) |
| OS, median months (95% CI) | 8.4 (4.3, NR) | NR (18.6, NR) |
| Response category . | PTCL (n = 16) . | CTCL (n = 19) . |
|---|---|---|
| ORR (CR + PR) | ||
| ORR, n (%) | 8 (50.0) | 6 (31.6) |
| 95% Confidence interval (CI) | (24.7, 75.3) | (12.6, 56.6) |
| Best overall response, n (%) | ||
| CR | 3 (18.8) | 0 |
| PR | 5 (31.3) | 6 (31.6) |
| Stable disease | 1 (6.3) | 6 (31.6) |
| Progressive disease | 6 (37.5) | 6 (31.6) |
| Unknown | 1 (6.3) | 1 (5.3) |
| Time to response, median months (range) | 1.9 (1.6-3.5) | 2.4 (1.6-3.8) |
| PFS, median months (95% CI) | 8.3 (1.4, NR) | 4.5 (1.0-13.8) |
| OS, median months (95% CI) | 8.4 (4.3, NR) | NR (18.6, NR) |
The Clopper-Pearson CI is presented. Patients with no postbaseline response assessment are represented as having an “unknown” response. Percentages are based on the number of patients in each indication.
NR, not reached at the time of this analysis; PR, partial response.